1921
Volume 102, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

There is no abstract available for this article.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.20-0230
2020-04-03
2020-06-02
Loading full text...

Full text loading...

/deliver/fulltext/14761645/102/5/tpmd200230.html?itemId=/content/journals/10.4269/ajtmh.20-0230&mimeType=html&fmt=ahah

References

  1. Yao X et al., 2020. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. https://doi.org/10.1093/cid/ciaa237.
    [Google Scholar]
  2. Weston S, Haupt R, Logue J, Matthews K, Frieman BM, 2020. FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro. bioRXiv.
    [Google Scholar]
  3. Dowall SD et al., 2015. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo Guinea pig model. J Gen Virol 96: 34843492.
    [Google Scholar]
  4. De Lamballerie X, Boisson V, Reynier JC, Enault S, Charrel RN, Flahault A, Roques P, Le Grand R, 2008. On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 8: 837839.
    [Google Scholar]
  5. Paton NI, Lee L, Xu Y, Ooi EE, Cheung YB, Archuleta S, Wong G, Wilder-Smith A, 2011. Chloroquine for influenza prevention: a randomized, double-blind, placebo controlled trial. Lancet Infect Dis 11: 677683.
    [Google Scholar]
  6. Sperber K, Louie M, Kraus T, Proner J, Sapira E, Lin S, Stecher V, Mayer L, 1995. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther 17: 622636.
    [Google Scholar]
  7. Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B, Tran HT, Simmons CP, 2010. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 4: e785.
    [Google Scholar]
  8. Gautret P et al., 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. https://doi.org/10.1016/j.ijantimicag.2020.105949.
    [Google Scholar]
  9. Gao J, Tian Z, Yang X, 2020. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14: 7273.
    [Google Scholar]
  10. National Academies of Sciences, Engineering, and Medicine, 2017. Integrating Clinical Research into Epidemic Response: the Ebola Experience. Washington DC: The National Academies Press.
    [Google Scholar]
  11. ClinicalTrials.gov, 2020 (NCT04315896). Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) (HYDRA). Available at: https://clinicaltrials.gov/ct2/show/NCT04315896?cond=NCT04315896&draw=2&rank=1. Accessed March 27, 2020.
    [Google Scholar]
  12. ClinicalTrials.gov, 2020 (NCT04318015). Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact with COVID-19 Patients (PHYDRA Trial) (PHYDRA). Available at: https://clinicaltrials.gov/ct2/show/NCT04318015?term=NCT04318015&draw=2&rank=1. Accessed March 27, 2020.
    [Google Scholar]
  13. ClinicalTrials.gov, 2020 (NCT04318444). Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19). Available at: https://clinicaltrials.gov/ct2/show/NCT04318444?term=NCT04318444&draw=2&rank=1. Accessed March 27, 2020.
    [Google Scholar]
  14. ClinicalTrials.gov, 2020 (NCT04321278). Safety and Efficacy of Hydroxychloroquine Associated with Azithromycin in SARS-CoV2 Virus (Alliance Covid-19 Brasil II). Available at: https://clinicaltrials.gov/ct2/show/NCT04321278?term=NCT04321278&draw=2&rank=1. Accessed March 27, 2020.
    [Google Scholar]
  15. ClinicalTrials.gov, 2020 (NCT04308668). Post-exposure Prophylaxis/Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP). Available at: https://clinicaltrials.gov/ct2/show/NCT04308668?term=NCT04308668&draw=2&rank=1. Accessed March 27, 2020.
    [Google Scholar]
  16. ClinicalTrials.gov, 2020 (NCT04304053). Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention (HCQ4COV19). Available at: https://clinicaltrials.gov/ct2/show/NCT04304053?term=NCT04304053&draw=2&rank=1. Accessed March 27, 2020.
    [Google Scholar]
  17. ClinicalTrials.gov, 2020 (NCT04316377). Norwegian Coronavirus Disease 2019 Study (NO COVID-19). Available at: https://clinicaltrials.gov/ct2/show/NCT04316377?term=NCT04316377&draw=2&rank=1. Accessed March 27, 2020.
    [Google Scholar]
  18. ClinicalTrials.gov, 2020. (NCT043032990). Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID19: A Randomized Control Trial (THDMS-COVID19). Available at: https://clinicaltrials.gov/ct2/show/NCT04303299?term=NCT04303299&draw=2&rank=1. Accessed March 27, 2020.
    [Google Scholar]
  19. Nord JE, Shah PK, Rinaldi RZ, Weisman MH, 2004. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum 33: 336351.
    [Google Scholar]
  20. Chen C, Zhou Y, Wang DW, 2020. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. https://doi.org/10.1007/s00059-020-04909-z.
    [Google Scholar]
  21. Taylor WR, White NJ, 2004. Antimalarial drug toxicity: a review. Drug Saf 27: 2561.
    [Google Scholar]
  22. ClinicalTrials.gov, 2020 (NCT04280705). Adaptive COVID-19 Treatment Trial (ACTT). Available at: https://clinicaltrials.gov/ct2/show/NCT04280705?cond=NCT04280705&draw=2&rank=1. Accessed March 30, 2020.
    [Google Scholar]
  23. Kupferschmidt K, Cohen J, 2020. Race to find COVID-19 treatments accelerates, WHO launches megatrial to test repurposed drugsand experimental drug candidates. Science 367: 14121413.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.20-0230
Loading
  • Received : 29 Mar 2020
  • Accepted : 30 Mar 2020
  • Published online : 03 Apr 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error